Vaxcyte, Inc. PCVX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$320.62M-30.1% | -$246.51M-15.8% | -$212.83M-27.8% | -$166.57M-18.4% | -$140.72M-2.7% | ||
| $2.95M-60.7% | $7.5M+145% | $3.06M+6.4% | $2.88M-2.6% | $2.96M+3.2% | ||
| $37.96M+5.5% | $36M+2.0% | $35.31M-4.4% | $36.93M+20.6% | $30.62M+25.6% | ||
| -$269K-101% | $21.67M— | —— | —— | -$29.16M-193% | ||
| -$15.57M-313% | $7.3M— | —— | —— | -$4.39M+52.9% | ||
| $8.74M-8.4% | $9.55M— | $0-100% | $6.67M+345% | $1.5M-54.5% | ||
| $2.91M+26.2% | $2.3M+8.0% | $2.13M+1.1% | $2.11M+10.0% | $1.92M-0.2% | ||
| -$1.29M-104% | $33.14M— | —— | —— | $16M-62.9% | ||
| -$280.63M-24.8% | -$224.83M-56.9% | -$143.31M-18.3% | -$121.17M+27.1% | -$166.27M-49.3% | ||
| $2.11M-20.6% | $2.65M-30.6% | $3.82M+111% | $1.81M-66.6% | $5.42M+34.9% | ||
| $584.13M+99.6% | $292.65M+14.6% | $255.32M-26.9% | $349.05M+11.0% | $314.49M-61.4% | ||
| $24.88M-63.5% | $68.22M+78.0% | $38.33M-8.9% | $42.07M+61.4% | $26.07M+6.3% | ||
| -$233.41M-303% | $115.13M-5.0% | $121.17M+55.9% | $77.74M-37.0% | $123.32M+122% | ||
| $9.03M+164% | $3.42M+1,016% | $306K-90.5% | $3.24M-46.5% | $6.05M— | ||
| $9.3M+823% | $1.01M-74.7% | $3.98M+455% | $717K-86.4% | $5.29M+388% | ||
| $601.58M+24,883% | $2.41M+166% | -$3.67M-246% | $2.52M+232% | $759K-84.5% | ||
| -$664K-477% | $176K-39.5% | $291K-63.6% | $800K-31.7% | $1.17M-13.2% | ||
| $86.88M+181% | -$107.12M-320% | -$25.52M+36.4% | -$40.11M+2.2% | -$41.03M+93.8% | ||
| $3.11M+12.6% | $2.76M+22.1% | $2.26M-49.6% | $4.49M-8.5% | $4.91M-57.9% | ||
| -$2.2M-233% | $1.66M+110% | $789K-96.9% | $25.71M+288% | $6.62M+162% | ||
| -$15.02M-341% | $6.23M— | —— | —— | -$14.42M-273% | ||
| $54.85M— | —— | $19.99M-43.1% | $35.13M+334% | $8.09M— | ||
| -$1.29M-104% | $33.14M— | —— | —— | $16M-62.9% | ||
| $0-100% | $34.8M— | —— | —— | $17.58M-61.2% | ||
| $16.88M+46.3% | $11.54M+2.0% | $11.32M+8.0% | $10.48M+59.9% | $6.55M+47.0% | ||
| $8.74M-8.4% | $9.55M— | $0-100% | $6.67M+345% | $1.5M-54.5% | ||
| $2.91M+26.2% | $2.3M+8.0% | $2.13M+1.1% | $2.11M+10.0% | $1.92M-0.2% | ||
| $12.69M+120% | $5.77M-29.9% | $8.22M+3.5% | $7.94M-62.8% | $21.33M-18.0% | ||
| $340.63M-2.1% | $347.97M-0.6% | $350.2M-11.2% | $394.48M-10.0% | $438.49M+66.4% | ||
| $24.88M-63.5% | $68.22M+78.0% | $38.33M-8.9% | $42.07M+61.4% | $26.07M+6.3% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $601.85M— | —— | $0— | $0— | $0— | ||
| $9.03M+164% | $3.42M+1,016% | $306K-90.5% | $3.24M-46.5% | $6.05M+1.1% | ||
| $6.34M+222% | $1.97M-6.1% | $2.1M— | $0-100% | $3.89M-49.2% | ||
| -$1.29M-104% | $33.14M— | —— | —— | $16M-62.9% | ||
| -$282.73M-24.3% | -$227.49M-54.6% | -$147.13M-19.6% | -$122.98M+28.4% | -$171.7M-48.8% | ||
| -$282.73M-24.3% | -$227.49M-54.6% | -$147.13M-19.6% | -$122.98M+28.4% | -$171.7M-48.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vaxcyte, Inc. generate?
- Vaxcyte, Inc. (PCVX) generated -$769.9M in operating cash flow over the trailing twelve months.
- What is Vaxcyte, Inc.'s free cash flow?
- After $10.4M of capital expenditures, Vaxcyte, Inc.'s free cash flow was -$780.3M over the trailing twelve months, down 61.9% year over year.
- Where does Vaxcyte, Inc.'s cash flow data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.